Cargando…

Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment

BACKGROUND: Immune checkpoint blockade is an emerging treatment for T cell non-Hodgkin’s lymphoma (T-NHL), but some patients with T-NHL have experienced hyperprogression with undetermined mechanisms upon anti–PD-1 therapy. METHODS: Single-cell RNA-Seq, whole-genome sequencing, whole-exome sequencing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yumei, Hu, Simeng, Li, Ruoyan, Jin, Shanzhao, Liu, Fengjie, Liu, Xiangjun, Li, Yingyi, Yan, Yicen, Liu, Weiping, Gong, Jifang, Yang, Shuxia, Tu, Ping, Shen, Lin, Bai, Fan, Wang, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977500/ https://www.ncbi.nlm.nih.gov/pubmed/36649072 http://dx.doi.org/10.1172/jci.insight.164793

Ejemplares similares

Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma
por: Liu, Xiangjun, et al.
Publicado: (2022)

High Expression of IKZF2 in Malignant T Cells Promotes Disease Progression in Cutaneous T Cell Lymphoma
por: XU, Bufang, et al.
Publicado: (2021)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Differential molecular programs of cutaneous anaplastic large cell lymphoma and CD30-positive transformed mycosis fungoides
por: Lai, Pan, et al.
Publicado: (2023)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
por: Faure, Marjorie, et al.
Publicado: (2018)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer
por: Chen, Shiyun, et al.
Publicado: (2021)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
por: Chen, Shiyun, et al.
Publicado: (2023)

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
por: Xiong, Donghai, et al.
Publicado: (2018)

Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports
por: Lin, Zhuangbin, et al.
Publicado: (2020)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

Hyperprogression of a spindle‐cell squamous carcinoma of the esophagus after esophagectomy
por: Ji, Yanli, et al.
Publicado: (2022)

Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence
por: Zheng, Jianpei, et al.
Publicado: (2023)

Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report
por: Occhipinti, Mario, et al.
Publicado: (2018)

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy
por: Wakiyama, Hiroaki, et al.
Publicado: (2022)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
por: Gong, Caifeng, et al.
Publicado: (2023)

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
por: Wang, Xueping, et al.
Publicado: (2023)

Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature
por: Liu, Chao, et al.
Publicado: (2021)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report
por: Yang, Ning, et al.
Publicado: (2020)

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
por: Liu, Xiaojun, et al.
Publicado: (2022)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
por: Zhou, Rui, et al.
Publicado: (2023)

Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma
por: Klemen, Nicholas D., et al.
Publicado: (2022)

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Hyperprogression: A novel response pattern under immunotherapy
por: Han, Xue‐jiao, et al.
Publicado: (2020)

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
por: Rocha, Pedro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u7pfhus1lafkasg6hmniuaec3u